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Abstract
Two recent Phase III clinical trials to investigate an intravaginal ring for preventing HIV infec-
tion demonstrated that adherence to prescribed device use was a primary driver of efficacy.
Surrogate methods for determining adherence in the studies were limited in their inability to
monitor temporal patterns of use and allow deconvolution of the effects of adherence and
device efficacy on HIV infection rates. To address this issue, we have developed functional-
ity in an intravaginal ring to continuously monitor when the device is being used and maintain
a log of adherence that can be accessed by clinicians after it is removed. An electronic mod-
ule fabricated with common, inexpensive electronic components was encapsulated in a sili-
cone intravaginal ring. The device uses temperature as a surrogate measure of periods of
device insertion and removal, and stores a record of the data for subsequent retrieval. The
adherence-monitoring intravaginal ring accurately recorded the device status over 33 simu-
lated IN-OUT cycles and more than 1000 measurement cycles in vitro. Following initial in
vitro testing in a temperature-controlled chamber, the device was evaluated in vivo in sheep
using a predetermined insertion/removal pattern to simulate intravaginal ring use. After
insertion into the vaginal cavity of a sheep, the logged data correctly indicated the device
status over 29 hours of continuous measurement including three cycles of insertion and
removal. The device described here is a promising, low-cost method for real-time adherence
assessment in clinical trials involving medicated intravaginal rings or other intravaginal
devices.
Introduction
The ability to assess adherence to therapy in clinical trials is essential to accurately evaluate the
efficacy of HIV infection prevention methods. Four recent clinical trials have demonstrated
that pre-exposure prophylaxis (PrEP) regimens may prevent HIV infection in a significant
proportion of individuals [1–5]; however, two additional HIV PrEP trials showed no efficacy
[6, 7]. The trial failures were due in large part to poor adherence to the prescribed antiretrovi-
ral dosing regimens [8]. The importance of adherence in topical PrEP is underscored in the
results of the CAPRISA 004 trial of a 1% tenofovir vaginal gel. The decrease in HIV infection
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was 54% in women with over 80% adherence to prescribed, pericoital gel use compared to 28%
in women with less than 50% adherence [3]. Self-reporting adherence has been shown to be
highly inaccurate: in the Carraguard microbicide trial, participants reported 94% gel use, but a
dye indicator on the applicators showed only 61% of returned applicators had been used in
43% of sex acts [9]. Assessment of intravaginal ring (IVR) adherence is more difficult because
a single IVR is often used for one month or more, and can be removed for long periods. The
ASPIRE clinical trial of an IVR delivering dapivirine showed increased efficacy against HIV-1
infection in subgroups exhibiting the highest adherence; however, accurate assessment of con-
tinuous IVR use over 1 month was difficult using the metrics of amount of dapivirine recov-
ered from used devices and plasma dapivirine concentrations at clinic visits [5].
Electronic devices have been used previously for measuring adherence to medication, and
include electronic pill monitors and inhaler dose monitors. The costs and benefits of these
devices have been reviewed extensively [10–16]. Drawbacks of existing technologies include
high cost, reliability, and lack of correlation with therapy adherence, i.e. opening the pill bottle
as indicated by a pill monitor does not indicate ingestion of the pill. Recently, Malcolm, et al.
reported a method for measuring adherence to intravaginal implant use by monitoring vaginal
temperature using a commercially available DST nano-T implantable temperature logger
(Star-Oddi, Gardabaer, Iceland) embedded in the device [17]. The DST-nano-T devices encap-
sulated in silicone tubing of varying wall thickness to approximate an IVR accurately measured
environmental temperature changes during 7 days of continuous monitoring in vitro. The
devices also correctly recorded a series of insertion and removal events at 8 min intervals over
7 days of continuous use following vaginal insertion in three cynomolgus macaques. The cost
of a single DST nano-T temperature logger (US$340), however, limits the potential of these
devices to be widely adopted in large-scale clinical trials, particularly in resource-limited set-
tings such as sub-Saharan Africa.
We report here an adherence monitoring IVR design that utilizes comparison of measured
device temperature to a predetermined reference value to determine the insertion/removal sta-
tus of the device. The custom electronic design is based on inexpensive, commercially available
components, and a novel data reduction method allows for storage of up to 2048 status read-
ings in only 256 bytes of non-volatile memory for retrieval after IVR removal.
Materials and methods
Device fabrication
The electronics modules were manufactured using industry standard printed circuit board
(PCB) fabrication and surface-mount assembly methods, and consisted of a single ca. 5
mm × 12 mm PCB containing all electronic components including the thermistor temperature
sensor and a separate battery pack containing two 1.55V SR416 silver oxide batteries (Fig 1).
Electronic components were purchased from Digikey (Thief River Falls, MN, USA). The PCBs
were fabricated by Sunstone Circuits (Mulino, OR, USA) and board assembly was completed
by Screaming Circuits (Canby, OR, USA). Silicone IVRs with an open cavity for the electronics
module were fabricated by injection molding from liquid silicone resin (MED-4840 LSR,
Nusil, Carpenteria, CA, USA) using a custom single cavity mold and a laboratory-scale injec-
tion molding machine designed and constructed in-house [18]. Assembled electronics mod-
ules were sealed in the IVR using a silicone adhesive (MED3-4213, Nusil, Carpenteria, CA,
USA) so that the electronics module and battery are completely encased in silicone and with
no contact with vaginal fluid.
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In vitro evaluation
The performance of the adherence IVR was evaluated in vitro by exposing the devices to con-
trolled temperatures simulating insertion and removal events. Devices were placed in a small
aluminum enclosure with a flexible silicone heater (Watlow, St. Louis, MO, USA) and solid-
state temperature controller (CT325, Minco, Minneapolis, MN, USA) providing accurate
(±0.2˚C) temperature control. The time, controller temperature set-point, and measured tem-
perature were logged using a PC-based data acquisition system (National Instruments USB-
6002 DAQ, Austin, TX, USA) using software written in the LabView development environment
(National Instruments). For experiments spanning multiple days, the enclosure temperature
was cycled between an “IN” state (~37˚C) and “OUT” state (ambient, ~25˚C) at predetermined
intervals to simulate a sequence of IVR insertions and removals.
In order to determine the response time of the adherence monitor to temperature change,
the thermistor voltage, Vth was measured as a function of ambient temperature as the device
was cycled alternately between chambers held at 28˚C and 37˚C. Values of Vth were converted
to temperature using a second-order polynomial fit to a five point temperature calibration
curve over the range 25˚C -44˚C. The device response time was calculated as the time required
to heat from 10% to 90% of the full-scale temperature difference (28.9˚C to 36.1˚C) or to cool
from 90% to 10%.
Simulated adherence monitoring in sheep
For in vivo evaluation in sheep, the adherence module was incorporated into a modified IVR
design consisting of a standard silicone pod-IVR [18, 19] containing no drug pods with the
module inserted into an additional hollow tubular compartment added to span the center of
the ring. The central compartment configuration, rather than embedding the electronics mod-
ule in the outer silicone ring, was used for the initial sheep study to allow facile access to the
circuit components during testing. Devices were programmed, powered, and placed in Sleep
mode, and then inserted into the central compartment and sealed with silicone adhesive.
The adherence-monitoring IVR was evaluated in a Rambouillet X Columbia sheep at the
Colorado State University Preclinical Surgical Research Laboratory (Fort Collins, CO, USA).
A schedule of ring insertion and removal was is shown in Table 1. The IVR was immersed in
warm water bath (50˚C) to initiate data logging, and remained in the warm bath until insertion
Fig 1. Adherence-monitoring IVR prototype. (a) Adherence IVR prototype with electronics module
embedded in IVR elastomer circumference as used in in vitro simulation experiments. For clarity, the IVR is
shown prior to sealing the circuit board and cylindrical battery pack in place using silicone adhesive. (b) Close-
up of prototype electronics module. (c) Cutaway 3D model of adherence IVR prototype used in sheep study.
The electronics module and battery are enclosed in a central compartment rather than sealed in the IVR
circumference to allow access to the electronics during initial in vivo evaluation. A portion of the central
compartment wall is removed in the drawing to expose the electronics module and battery.
https://doi.org/10.1371/journal.pone.0174729.g001
An intravaginal ring for real-time evaluation of adherence to therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0174729 April 6, 2017 3 / 15
in the sheep vaginal cavity. The IN/OUT status of the IVR was measured and stored in non-
volatile memory on a 1.00 min interval, using a reference temperature of 34.4˚C. The inser-
tion/removal pattern was followed for 29 hours, whereupon the ring was removed and logging
stopped by cutting through the ring to sever the battery connection to the PCB. The insertion
and removal periods were based on the workflow in the animal facility during the two days of
the study, and were designed to provide both short and long insertion and removal periods
with minimal disturbance to the animal. The stored IN/OUT data stream was downloaded
from the device to a PC using the Microchip PICkit3 programmer USB interface, and the data
in hexadecimal format was converted to a series of binary (0 or 1) values indicating IVR OUT
or IN.
The sheep study was performed according to NIH guidelines at Colorado State University,
a facility accredited by the Association for Assessment and Accreditation of Laboratory Ani-
mal Care (AAALAC). Protocols were approved by Institutional Animal Care and Use Com-
mittees at Colorado State University (Fort Collins, CO, USA; Animal Welfare Assurance
Number: A3572-01) under approval #12-3704A. Implantation of IVRs was performed under
minimal physical restraint without causing undue stress or pain to the sheep. Sheep were
flipped, hooded and hobbled, and placed in lateral recumbency. The perineal region was
prepped with multiple scrubs of povidine iodine alternated with isopropyl alcohol. The device
was inserted into the cranial vagina using a sterile gloved finger lubricated with medical-grade
lubricant gel. A non-absorbable nylon suture tied to the IVR was allowed to extend outside of
the vulva to indicate that the ring had not been expelled, and to aid in removal of the ring dur-
ing removal/reinsertion procedures. Sheep were minimally restrained while the IVR was
removed from the vagina using a suture traction. Devices were re-inserted using similar meth-
ods. The study was non-terminal.
Results
Hardware design
The PIC12F683 microcontroller (Microchip Technology, Inc., Chandler, AZ, USA) was cho-
sen as the basis of the adherence-monitoring IVR design. The PIC12F683 is a miniature 8-pin,
Flash-based, 8-bit CMOS microcontroller, with a size of 4 mm × 4 mm × 0.9 mm in the DFN
surface-mount package. The PIC12F683 has numerous features making it a good choice for
this application, including: low-power sleep and operating modes to preserve battery life (50
Table 1. In vivo sheep study events timeline.
Time IVR Status Actual Temperature (˚C) Expected IVR Response*
9:45 AM Logging Start, 50˚C Bath 50˚C IN
10:17 AM Insert in vaginal vault
1:11 PM Remove to 50˚C bath
1:18 PM Remove to RT 25˚C OUT
1:29 PM Insert in vaginal vault 41˚C IN
3:35 PM Remove to RT 25˚C OUT
3:52 PM Insert in vaginal vault 41˚C IN
7:57 AM Remove to RT 25˚C OUT
2:31 PM Stop Logging 25˚C none
RT, room temperature (~25˚C)
* IN represents binary 1, OUT represents binary 0
https://doi.org/10.1371/journal.pone.0174729.t001
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nA standby current; 11 μA operating current at 32 kHz), analog comparator with on-chip pro-
grammable voltage reference, external oscillator functionality for precision long-term timing
stability, six I/O pins individually programmable for sensor input or LED indicator output,
and 256 byte non-volatile EEPROM memory capable of storing 2048 1-bit IN/OUT readings.
The adherence monitor consists of the following functional modules (Fig 2A):
Fig 2. Electronics module design and function. (a) Diagram of adherence IVR electronics module
showing major functional components (boxes) and dataflow (arrows). (b) Plot showing relationships between
reference temperature, comparator reference voltage (Vref), and the 4-bit Vref generator parameter. Each
point represents a reference temperature that is set in software by the generator 4-bit value (0–15). Here a
generator value of 11 is set to select a reference temperature of 34˚C. Dotted lines indicate Vref values
selected for IN/OUT determination and “Logging On” “Logging Off” functionality in the in vitro and in vivo
testing of adherence IVR devices.
https://doi.org/10.1371/journal.pone.0174729.g002
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1. Battery: The device can operate with a voltage input range of 2.0 to 5.5 V. Two silver oxide
coin cell batteries (SR416) provided a nominal 3.1 V input (Vdd) voltage. For debugging
and testing, the electronics module was powered by a variable DC power supply, and power
for PIC12 microcontroller programming and data retrieval is provided through the pro-
gramming/data interface connection.
2. Programming/Data Interface. A 5-pin interface is used for microcontroller programming
and data transfer from the IVR to a PC for retrieval of logged status values. For the proto-
type device described here, all programming and data transfer operations utilized the
Microchip PICkit 3 programming interface and the Microchip MPLabX Integrated Devel-
opment Environment (IDE).
3. External crystal clock. A precision quartz crystal tuning fork provides a stable clock to drive
all device timing. The crystal’s 32.768 kHz oscillations are counted into the PIC12 16-bit
incrementing counter so that one timer rollover occurs every 2 s. This rollover initiates a
wake from the microcontroller sleep state (wake every 2 sec), and all device timing (e.g.
measurement interval) is a multiple of 16-bit timer cycles. The 200 ppm accuracy of the
quartz crystal leads to timing accuracy of 6 ms h-1 (4.3 s per 30 days).
4. LED output. The general purpose I/O pin (GP2) is connected to an LED, allowing visual
indication of device status, temperature measurement, and EEPROM writing. LED output
is configured and enabled in software and allows for LED indicators in debugging mode,
and the ability to turn off LED functionality programmatically to decrease device power
consumption during long-term use.
5. Temperature sensor. A 10 kO precision thermistor temperature sensor in a resistive divider
circuit provides a voltage input (Vth) to the PIC12 comparator (GP1, CIN-) that is propor-
tional to device temperature. The magnitude of Vth is a fraction of the battery voltage Vdd
and varies linearly with thermistor temperature. The comparator compares this voltage to
an internally generated reference voltage (Vref). Comparator output is high (1) when Vth >
Vref and low (0) when Vth < Vref. The value of Vref is set programmatically with a 4-bit
parameter, allowing a range of reference temperatures to be used for implementing various
device functions such as starting or stopping data logging to internal memory.
Device software
The device’s embedded software was written in C using the Microchip XC8 compiler in the
MPLAB X Integrated Development Environment (IDE). A code flow chart is shown in Fig 3.
The compiled program is downloaded to the device using the PICkit 3 programmer. The soft-
ware implements three main functions: measuring and saving to memory the 1-bit value rep-
resenting device IN or OUT, enabling data logging, and disabling data logging. All are based
on comparison of Vth to a Vref generated in the microcontroller. Following completion of the
initialization routine, the device enters a low-power sleep mode in a continuous loop waiting
for 16-bit timer rollover. At each rollover (65538 counts at 32.768 kHz = 2 s), the device wakes
and evaluates three options: (1) run the log comparator output (IN or OUT status) subroutine
(green in Fig 3), (2) run the logging on/off subroutine (blue in Fig 3), or (3) return to sleep.
The time interval for checking logging on/off status and logging comparator output is set in
the program code. For prototype evaluation, the logging on/off subroutine was run every 2
rollovers (4 sec), and the data logging interval was varied from 10 s (5 wake cycles) to 5 min
(150 wake cycles) depending on the test conditions.
An intravaginal ring for real-time evaluation of adherence to therapy
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Initially, a status bit indicating logging disabled prevents the execution of the logging
(green) subroutine, and at wake the device queries if it is time to enter the logging on/off
(blue) subroutine. If yes, the device measures Vth and compares it to the “Logging On” Vref
value. The relationship between Vref and temperature is shown in Fig 2B. If Vth > Vref for a set
number of wake cycles (typically 20 sec), data logging is enabled prior to returning to the sleep
state. This has the effect of allowing data logging to be switched on by heating the device above
the temperature corresponding to the “Logging On” Vref value (typically 50˚C). Once logging
is enabled, subsequent wake cycles will run the green data logging subroutine at the appropri-
ate sampling interval set in the program. When logging is enabled, each blue subroutine mea-
sures Vth, compares it to the “Logging Off” Vref (typically 5˚C), and turns off logging if Vth <
Vref. In typical real-world applications, the “Logging Off” functionality is not used and data
logging is stopped by removing power (cutting the ring and battery connection).
When logging is enabled and the appropriate number of wake cycles have been completed
to reach the set logging interval, the data logging (green) subroutine is entered. The program
sets appropriate Vref for determining IN/OUT status (typically ~35˚C) at one comparator
input and reads Vth at the other. The output is “1” of Vth > Vref (IN) and “0” if Vth < Vref
(OUT). This 1-bit value is stored in the current data byte. When 8 IN/OUT bits are accumu-
lated, the data byte is written to non-volatile EEPROM memory. The built-in PIC12F683
EEPROM size of 256 bytes allows storage of 2048 IN/OUT readings. Additionally, the LED
may be flashed to indicate a measurement or other device status. The current implementation
uses a short LED flash to indicate power on, a 3 sec LED on to indicate logging started or
stopped, and a short flash to indicate a logged data value. More complex LED output enabled
for debugging has included a double flash for “IN” measurement and single flash for “OUT”
Fig 3. Flow diagram for adherence IVR embedded code. Major device program functions are indicated by color with arrows showing program
execution flow: device initialization (orange), sleep state (gray), logging status control and timing (blue), and data logging and storage (green)
functions.
https://doi.org/10.1371/journal.pone.0174729.g003
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measurement with three flashes indicating a successful data write to EEPROM. The LED func-
tionality may be enabled or disabled programmatically in software. During long-term testing
and in vivo evaluation, the LED functionality is minimized to preserve battery life.
Laboratory evaluation
The in vitro performance of an adherence-monitoring IVR undergoing multiple temperature
cycles between 25˚C and 40˚C to simulate repeated insertion and removal over 100 h (4.2
days) is shown in Fig 4. The device accurately monitors the IVR status (temperature relative to
34.4˚C) over 33 simulated IN/OUT cycles and 1192 measurements made on a 5 min interval.
Fig 4. In vitro evaluation of adherence IVR. Response of adherence IVR over 100 h using a simulated
insertion/removal cycle of 2.5 h in and 0.5 h out (lower plot) using a programmed temperature test apparatus.
Data represent the IN/OUT status (0 or 1) logged at a 5 min interval. The upper plot shows expansion of data
at 6, 48, and, 96 h for three adherence IVRs measuring simultaneously. Vertical dotted lines indicate transition
to “IN” temperature for each cycle shown. The temporal alignment of “IN” measurements does not vary
between the three devices over 96 h of measurement. The time required for the device to respond to a
simulated insertion or removal event was determined using the temperature-time data shown in Fig 5. The
device was exposed to three repeated step changes in temperature between 28˚C and 37˚C, and response
was calculated as the time required for the device to measure the range of 10% to 90% of the total 9˚C
temperature change (28.9˚C and 36.1˚C). For the step from 28˚C to 37˚C (simulated insertion), the 10%-90%
time was 1.84 ± 0.006 min. For the step from 37˚C to 28˚C (simulated removal), the 90% to 10% time was
1.96 ± 0.096 min.
https://doi.org/10.1371/journal.pone.0174729.g004
Fig 5. Adherence IVR temperature response analysis. (a) Temperature measured by the thermistor as a
function of time during three cycles of alternating between two controlled temperature chambers maintained
at 28˚C and 37˚C, respectively. (b) Zoomed data for first cycle showing individual temperature readings
collected at 10 s intervals. The lower and upper gray dotted lines indicate the values at 10% and 90%,
respectively, of the full-scale measured temperature change.
https://doi.org/10.1371/journal.pone.0174729.g005
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This is the equivalent of one IVR removal and replacement every 1.5 days for 50 days using a 1
h measurement cycle. The measurement frequency (1s –days) and reference temperatures (0–
45˚ C) are set in software and cover a broad range of values appropriate for laboratory evalua-
tion and long-term clinical use. The temporal accuracy of the device is shown in the expansion
plot (Fig 4), where the simulated IVR replacements (temperature ~ 40˚C) at approximately 6,
48, and 96 hours are captured at the same time by each of the three devices under test.
Sheep study
A single device was evaluated for 29 h over a series of three insertion/removal events in the
vaginal cavity of a sheep. Fig 6 shows the IVR response to the sequence of events. The timing
of the events is clearly captured by the device as shown by the alignment of the recorded data
with the symbols indicating each insertion or removal.
Discussion
The discordant results observed among HIV PrEP clinical trials clearly indicate the impor-
tance of adherence in determining successful prevention outcomes [8]. Sustained, topical
delivery of ARV agents and microbicides using IVRs has been suggested for improving adher-
ence; however, clinical data to support this assertion are limited [20, 21]. Real-time assessment of
adherence during IVR clinical trials could allow quantitative measurement of the relationship
between IVR use and HIV prevention efficacy. Until recently, no methods for real-time moni-
toring of IVR adherence had been reported. Boyd, et al. demonstrated proof-of-principle for
using IVR temperature as a surrogate measure of adherence [17]. They employed a commercially
available temperature logging device inserted in the vaginal cavity to continuously monitor
device temperature, and compared it to intravaginal (body) temperature to determine periods of
device insertion and removal. These devices store over 5000 temperature measurements for later
Fig 6. In Vivo Evaluation of Adherence IVR. Device response as a function of time for a series of insertion
and removal periods in a sheep vaginal model. The black trace is the logged data (1 min logging interval)
retrieved from the device at the study conclusion. The actual time for removal and insertion events is indicated
by the symbols above the black trace. The gray trace shows the temperature as a function of time for the three
ring dispositions: water bath (50˚C) sheep vaginal temperature measured at the start of the study (39˚C), and
ambient laboratory temperature (25˚C).
https://doi.org/10.1371/journal.pone.0174729.g006
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retrieval and have a measurement accuracy of 0.2˚C. The data collected during a 7 day macaque
study using these devices embedded in segments of silicone tubing showed that device tempera-
ture can accurately track insertion and removal patterns even in the presence of normal vaginal
temperature fluctuations. The $340 cost per device, however, limits the ability to incorporate
these devices into IVRs for widespread use, particularly in resource-limited settings. Addition-
ally, these are specialized devices from a single vendor, with a risk of limited availability due to
market or other circumstances.
Device design
The device described here offers a low-cost alternative for real-time temperature-based IVR
adherence monitoring. The design is based on the widely used 8-bit Microchip PIC12 micro-
controller platform. The circuit uses 8 discrete surface-mount components on a single PCB,
with a total cost for components, PCB fabrication, and assembly of US$6 in quantities of 5000,
including batteries. This is the cost for the device only and does not include IVR manufacture.
A number of characteristics and advantages of the PIC12F683 microcontroller are described
above. Use of the PIC12 internal comparator and non-volatile memory enabled the IVRs to
use only 8 circuit components and achieve the smallest possible PCB size. The PIC12 data
memory is limited to 256 bytes and required the use of a novel data reduction scheme to
achieve storage of 2048 IVR status values for retrieval following IVR use. Our approach was to
compare a measured voltage proportional to IVR temperature to a reference temperature to
determine IVR insertion or removal status, but to store the data in bytes containing eight
sequential 1-bit representations of OUT (0) or IN (1) instead of actual temperature values.
Data files are retrieved from the device in hexadecimal format, and direct conversion to binary
values results in a sequence of 0 and 1 values indicating IVR OUT or IN, respectively, at each
predetermined logging interval. An important aspect of the device design is the ability to
programmatically set the reference temperature through a simple software setting. For the
studies described here, a reference temperature of 34.4˚C was used. This temperature was
selected based on the temporal variation in macaque vaginal temperature described by Boyd
et al.[17] and the normal sheep body temperature measured in this study and by others,[22]
with a margin for error to prevent false readings of IVR removal. The reference temperature
will need to be optimized in clinical trial to accommodate differences between human and
sheep basal temperatures.
A second device functionality that enables the simple, compact circuit design is the use of
temperature readings to control device functions. As shown in the program flow diagram (Fig
3), data logging is started from the initial device sleep state when the measured thermistor volt-
age is above a reference value set programmatically. A reference corresponding to 50˚C was
used to initiate logging. Logging may be started by simply placing the device in a cup of hot
water for approximately 1 minute. Water is used here as a convenience, and any method of
raising the device temperature to 50˚C or more would work equally well. Similarly, logging is
stopped when the thermistor voltage is below a programmatically set “stop” threshold, easily
achieved by exposing the device to a low temperature such as a cup of ice water or a refrigera-
tor. A simpler method of stopping logging that may be more useful in a trial setting is to simply
cut the IVR elastomer to sever the battery wires and remove device power. The stored data is
retained in non-volatile memory in the unpowered device and may be retrieved through the
program/data interface as described above.
A limitation of using temperature as a surrogate measure of adherence is that in some cli-
mates, temperatures may exceed the reference temperature, and even body temperature at
times. Local temperatures at clinical sites used in the ASPIRE and Ring Study clinical trials of
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the dapivirine IVR are typically not high enough to be above the 34.4˚C reference temperature
used in these adherence IVR studies. Average high temperatures during the summer months
approach this limit in some areas of South Africa and Zimbabwe, and high temperatures for
individual summer days may exceed the reference or body temperatures. Issues associated
with high local temperatures can be mitigated to allow retrieval of usable adherence data even
in cases where ambient temperatures exceed the reference temperature. An IVR that is
removed and stored at ambient temperature will record diurnal temperature variations if the
daily ambient high temperature exceeds the reference temperature. It would be rare for the
low temperature, even on the hottest days, to be above a 34–35˚C reference temperature. This
diurnal pattern will be distinct, and can be correlated with historical temperature records or
temperatures measured at clinical sites as part of a trial protocol.
The adherence-monitoring IVR design is a modification of the established pod-IVR platform
that was developed specifically for controlled vaginal delivery of drug combinations. The pod-
IVR has been applied to delivery of small molecule ARV drugs for HIV [18, 19, 23–25] and
HSV [18, 26] prevention as well as to vaginal delivery of monoclonal antibodies [27] and bacte-
rial probiotics [28]. The pod-IVR consists of a silicone elastomer scaffold containing individual
embedded drug pods that act as independent delivery devices. The adherence-monitoring mod-
ule may be incorporated in the same manner as the drug pods, and drug release from the device
will be unaffected. The dimensions of the prototype adherence module described here was cho-
sen to be small enough to fit within a pod-IVR containing an expanded section as shown in Fig
1A, but large enough to allow manual soldering rework and other modifications during device
development to be easily carried out. The electronics layout has subsequently been further mini-
aturized to a circuit board size of 14 mm × 5.1 mm that will fit within the dimensions of a stan-
dard pod-IVR (8 mm cross-sectional diameter, 56 mm outer ring diameter). This is also the size
of the dapivirine IVR that has recently completed Phase 3 clinical trial [5]. Future efforts will
focus on further miniaturization of the electronics module and the incorporation of adherence-
monitoring functionality into pod-IVRs delivering ARV combinations.
Implementation of adherence monitoring functionality in IVR designs
The in vitro and in vivo studies reported here demonstrate feasibility of the adherence moni-
toring approach and device; however, there are a number of development and regulatory hur-
dles associated with successful incorporation of the monitoring device in a combination
product delivering one or more antiretroviral agents for HIV prophylaxis. The next steps in
device development will focus on miniaturization of the electronics module and long term
(28 days) in vitro and in vivo studies. The current devices are capable of this longer monitor-
ing time. With a memory capacity of 2048 values, logging with a 30 min data interval allows
continuous adherence monitoring for more than 42 days, and a 1 h interval increases this time
to 85 days.
The regulatory pathway for a combination product consisting of an IVR delivering one or
more antiretroviral agents modified with the adherence module is more complex than that of a
drug or device alone. For incorporation of the adherence monitor into an IVR for HIV preven-
tion, there are two primary regulatory concerns: (1) safety of the adherence module itself, and
(2) demonstrating that addition of the adherence module does not negatively affect the safety,
stability, or dreg release characteristics of the IVR. Because the primary mode of action (the
mode expected to have the greatest overall therapeutic effect) of the combination device is anti-
viral drug delivery, the FDA Center for Drug Evaluation and Research (CDER) has regulatory
jurisdiction, and clinical evaluation will take place under an Investigator New Drug (IND)
application using a series of clinical trials (Phase 1, Phase 2, Phase 3).The adherence module is
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being developed primarily, but not exclusively, for incorporation into the pod-IVR platform
that is currently in early clinical evaluation [26, 29]. Initial clinical evaluation of an adherence
IVR to demonstrate feasibility would be conducted on the device without drug product under
an Investigational Device Exemption (IDE) if the device is determined to be Significant Risk
(SR). A SR designation for the adherence monitoring IVR is likely because it is an implantable
device maintaining mucosal contact for more than 28 days. For initial clinical studies lasting
fewer than 28 days, however, it is likely that the device would be designated Non-significant
Risk (NSR), and evaluation could proceed without an IDE and only approval by the clinical
investigator’s Institutional Review Board (IRB). This initial evaluation without drug product
would provide a foundation of safety data to use in preparing the combination product IND as
well as serve as Phase 1 clinical evaluation of an IVR that could be used in placebo groups in
future clinical trials.
Implications for clinical trial adherence monitoring
Adherence monitoring in HIV prevention trials has traditionally been limited to participant
self-report or tracking of study materials (pill count or return of used gel applicators),
approaches that have led to inaccurate assessment of true product use [8–10]. The ASPIRE
dapivirine IVR trial incorporated an objective measure of adherence to IVR use in a large scale
study in sub-Saharan Africa [30, 31]. Returned IVRs were tested for residual dapivirine levels
to determine the amount of drug released. The distribution of residual dapivirine values was
bimodal with one peak at 24–25 mg residual DPV indicating IVRs were unused, and a second
peak at 20–21 mg indicating IVRs were used for 28 days. Using a length-adjusted analysis of
the residual DPV data, seroconverting subjects were binned into four adherence groups based
on the clinic visit with the lowest adherence for the three visits prior to HIV detection. A
strong correlation of protection with adherence group was observed (% risk reduction, inci-
dence per 100 person-years): no use (11%, 4.9), bottom third (29%, 3.1), middle third (58%,
1.9), top third (92%, 0.4). The placebo group exhibited an incidence of 4.7 per 100 person-
years. Plasma levels of dapivirine was also measured quarterly as an additional measure of IVR
use; however, insertion of the ring for 8 hours or more before a clinic visit resulted in identical
plasma levels to 28 days of continuous use. Although the residual dapivirine levels only pro-
vided a snapshot of total IVR use over one month and no temporal use data, the ASPIRE data
indicate that even imperfect and incomplete objective adherence data can lend valuable insight
into patterns of adherence and the relationship between adherence and product efficacy in a
clinical setting. The IVR use pattern obtained from the adherence module developed here
would allow a much more detailed analysis than was conducted in ASPIRE, including specific
time periods of IVR use, total drug dose during use period, self-report of IVR use and sexual
activity, and HIV infection status to extract the key pharmacokinetic-pharmacodynamic rela-
tionships that result in HIV prevention efficacy.
Incorporation into a clinical trial can follow several approaches. (1) For a Phase III (effi-
cacy) trial, all active and placebo IVRs can incorporate adherence devices. This will allow
determination of adherence and investigation of product efficacy in both perfect adherence
and non-adherence scenarios. Additionally, both placebo and active arms of trials can be mon-
itored for adherence to determine patterns of adherence in different groups. Because residual
dapivirine in returned IVRs and plasma dapivirine levels were surrogate measures of adher-
ence in ASPIRE, no method for determining IVR use in placebo groups was available. Signifi-
cant differences in adherence between active and placebo groups may indicate inadequate
study blinding, poor randomization of study groups, or other trial design issues. (2) Adherence
devices may be incorporated into a subset of Phase 3 study IVRs, both active and placebo. This
An intravaginal ring for real-time evaluation of adherence to therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0174729 April 6, 2017 12 / 15
will allow sub-group adherence data to be extrapolated to the larger study population in stud-
ies where it may be logistically difficult to include adherence monitoring for all study partici-
pants. Data from temperature-based adherence monitoring can also be combined with plasma
drug levels and residual drug in used IVRs to provide temporal IVR use data to increase accu-
racy of adherence assessment. (3) Devices can be incorporated into IVRs in Phase 1 and Phase
2 trials as a “perfect” measure of adherence that can be used to evaluate non-objective adher-
ence measures and to develop additional adherence endpoints, such as compounds adsorbed
into the IVR from vaginal fluids, drug levels in blood or other relevant compartments, and
residual drug in used IVRs.
Conclusions
A miniature, low-cost IVR device using readily available electronic components, can provide
accurate and quantitative determination of adherence to IVR-based HIV prevention methods.
Adherence has been shown to be a primary factor in PrEP and microbicide clinical trial fail-
ures, and adherence monitoring may allow more accurate evaluation of product efficacy, iden-
tify factors influencing product use, and enable early interventions to ensure successful
preventative therapy. Based on these initial in vitro and in vivo results, this adherence-monitor-
ing IVR merits further development and evaluation in preclinical and clinical studies.
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